Key result
Beta-blockers are prescribed to only 30% of Japanese patients with coronary artery disease, but lipophilic beta-blockers may effectively reduce all-cause mortality in this population.
Why the study?
Does beta-blocker therapy improve outcomes in Japanese patients with coronary artery disease in the era of percutaneous coronary intervention?
Does beta-blocker therapy improve outcomes in Japanese patients with coronary artery disease in the era of percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
This editorial highlights the underutilization of beta-blockers in Japanese CAD patients and emphasizes the need for randomized trials to establish their efficacy in the modern PCI era.
n the era of percutaneous coronary intervention (PCI), the importance of medical treatment for coronary artery disease (CAD) seems to have decreased. However, half of the decline in rates of death from CAD over the past 2 decades in the USA has been attributed to reductions in factors, and half to treatments, the main contributor the secondary-prevention medications, of which -blockers account for the largest portion. Calcium antagonists for the secondary prevention of MI are not recommended in Western populations.
No takes yet. Share an insight, caveat, or question.
Takuroh Imamura (2010) conducted an editorial in Coronary Artery Disease. Beta-blockers was evaluated. Beta-blockers are prescribed to only 30% of Japanese patients with coronary artery disease, but lipophilic beta-blockers may effectively reduce all-cause mortality in this population.
Synapse has enriched 10 related papers. Consider them for comparative context: